Cover Image
市場調查報告書

動脈粥狀硬化性心血管疾病:開發中產品分析

Atherosclerosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232865
出版日期 內容資訊 英文 252 Pages
訂單完成後即時交付
價格
Back to Top
動脈粥狀硬化性心血管疾病:開發中產品分析 Atherosclerosis - Pipeline Review, H2 2016
出版日期: 2016年11月09日 內容資訊: 英文 252 Pages
簡介

動脈粥狀硬化性心血管疾病,是由於高密度脂蛋白積蓄造成動脈肥厚化並硬化的疾病。會阻礙血流、引起嚴重的心血管障礙。症狀有胸部疼痛、四肢或動脈阻塞的部位疼痛、呼吸急促、疲勞感、意識障礙、血流不足造成腿部肌肉無力等。

本報告提供動脈粥狀硬化性心血管疾病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

動脈粥狀硬化性心血管疾病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

動脈粥狀硬化性心血管疾病:企業開發中的治療藥

動脈粥狀硬化性心血管疾病:大學/機關研究中的治療藥

動脈粥狀硬化性心血管疾病:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

動脈粥狀硬化性心血管疾病:企業開發中的產品

動脈粥狀硬化性心血管疾病:大學/機關研究中的產品

動脈粥狀硬化性心血管疾病的治療藥開發企業

  • Ache Laboratorios Farmaceuticos S/A
  • advanceCor GmbH
  • AFFiRiS AG
  • Amgen Inc.
  • Arisaph Pharmaceuticals, Inc.
  • Artery Therapeutics, Inc.
  • AstraZeneca Plc
  • Athera Biotechnologies AB
  • AtheroNova Inc.
  • Bayer AG
  • Campus Technologies Freiburg GmbH
  • Cardax Pharmaceuticals, Inc.
  • Cerenis Therapeutics Holding SA
  • ChemoCentryx, Inc.
  • CohBar, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • 第一三共
  • DoNatur GmbH
  • Dybly AG
  • Exicure, Inc.
  • GenKyoTex S.A.
  • Jenrin Discovery, Inc.
  • Johnson & Johnson
  • KineMed, Inc.
  • 興和
  • La Jolla Pharmaceutical Company
  • Lead Discovery Center GmbH
  • Merck & Co., Inc.
  • MI.TO. Technology S.r.L.
  • Omeros Corporation
  • OPKO Health, Inc.
  • 大塚集團
  • Resverlogix Corp.
  • The Medicines Company
  • Therapix Biosciences Ltd
  • Tolerys SA
  • Vascular Biogenics Ltd.
  • Vericel Corporation
  • Vitae Pharmaceuticals, Inc.
  • XBiotech USA, Inc.

動脈粥狀硬化性心血管疾病:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

動脈粥狀硬化性心血管疾病:最近的開發平台趨勢

動脈粥狀硬化性心血管疾病:暫停中的計劃

動脈粥狀硬化性心血管疾病:開發中止的產品

動脈粥狀硬化性心血管疾病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8629IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Pipeline Review, H2 2016, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.

Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 5, 43 and 14 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 25 and 4 molecules, respectively.Atherosclerosis.

Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Atherosclerosis Overview
  • Therapeutics Development
  • Atherosclerosis - Therapeutics under Development by Companies
  • Atherosclerosis - Therapeutics under Investigation by Universities/Institutes
  • Atherosclerosis - Pipeline Products Glance
  • Atherosclerosis - Products under Development by Companies
  • Atherosclerosis - Products under Investigation by Universities/Institutes
  • Atherosclerosis - Companies Involved in Therapeutics Development
  • Atherosclerosis - Therapeutics Assessment
  • Drug Profiles
  • Atherosclerosis - Dormant Projects
  • Atherosclerosis - Discontinued Products
  • Atherosclerosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Atherosclerosis, H2 2016
  • Number of Products under Development for Atherosclerosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Atherosclerosis - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
  • Atherosclerosis - Pipeline by advanceCor GmbH, H2 2016
  • Atherosclerosis - Pipeline by AFFiRiS AG, H2 2016
  • Atherosclerosis - Pipeline by Akcea Therapeutics Inc, H2 2016
  • Atherosclerosis - Pipeline by Amgen Inc., H2 2016
  • Atherosclerosis - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016
  • Atherosclerosis - Pipeline by ARMO Biosciences, Inc., H2 2016
  • Atherosclerosis - Pipeline by Artery Therapeutics, Inc., H2 2016
  • Atherosclerosis - Pipeline by Athera Biotechnologies AB, H2 2016
  • Atherosclerosis - Pipeline by Cardax, Inc., H2 2016
  • Atherosclerosis - Pipeline by Cerenis Therapeutics Holding SA, H2 2016
  • Atherosclerosis - Pipeline by ChemoCentryx, Inc., H2 2016
  • Atherosclerosis - Pipeline by CohBar, Inc., H2 2016
  • Atherosclerosis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Atherosclerosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Atherosclerosis - Pipeline by DoNatur GmbH, H2 2016
  • Atherosclerosis - Pipeline by Dybly AG, H2 2016
  • Atherosclerosis - Pipeline by GenKyoTex S.A., H2 2016
  • Atherosclerosis - Pipeline by HitGen LTD, H2 2016
  • Atherosclerosis - Pipeline by Jenrin Discovery, Inc., H2 2016
  • Atherosclerosis - Pipeline by Kang Stem Biotech Co., Ltd., H2 2016
  • Atherosclerosis - Pipeline by KineMed, Inc., H2 2016
  • Atherosclerosis - Pipeline by Kowa Company, Ltd., H2 2016
  • Atherosclerosis - Pipeline by La Jolla Pharmaceutical Company, H2 2016
  • Atherosclerosis - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Atherosclerosis - Pipeline by LipimetiX Development Inc, H2 2016
  • Atherosclerosis - Pipeline by Merck & Co., Inc., H2 2016
  • Atherosclerosis - Pipeline by Omeros Corporation, H2 2016
  • Atherosclerosis - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Atherosclerosis - Pipeline by Resverlogix Corp., H2 2016
  • Atherosclerosis - Pipeline by The Medicines Company, H2 2016
  • Atherosclerosis - Pipeline by Therapix Biosciences Ltd., H2 2016
  • Atherosclerosis - Pipeline by Tolerys SA, H2 2016
  • Atherosclerosis - Pipeline by Unity Biotechnology, Inc., H2 2016
  • Atherosclerosis - Pipeline by Vascular Biogenics Ltd., H2 2016
  • Atherosclerosis - Pipeline by Vericel Corporation, H2 2016
  • Atherosclerosis - Pipeline by Vicore Pharma AB, H2 2016
  • Atherosclerosis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016
  • Atherosclerosis - Pipeline by XBiotech Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Atherosclerosis - Dormant Projects, H2 2016
  • Atherosclerosis - Dormant Projects (Contd..1), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..2), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..3), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..4), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..5), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..6), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..7), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..8), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..9), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..10), H2 2016
  • Atherosclerosis - Dormant Projects (Contd..11), H2 2016
  • Atherosclerosis - Discontinued Products, H2 2016
  • Atherosclerosis - Discontinued Products (Contd..1), H2 2016
  • Atherosclerosis - Discontinued Products (Contd..2), H2 2016

List of Figures

  • Number of Products under Development for Atherosclerosis, H2 2016
  • Number of Products under Development for Atherosclerosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top